About Eton Pharmaceuticals
Eton Pharmaceuticals is a publicly listed company based in Barrington (United States) founded in 2013, and was acquired by Bausch & Lomb in February 2019. Sterile injectables are developed and commercialized by Eton Pharmaceuticals. Eton Pharmaceuticals has raised $20.06 million across 2 funding rounds from investors including Bausch & Lomb. The company has 31 employees. Eton Pharmaceuticals has completed 2 acquisitions, including Increlex and PKU GOLIKE. Eton Pharmaceuticals offers products and services including Alkindi Sprinkle, Galzin, Increlex, and PKU GoLike. Its focus areas include Diversified Pharmaceuticals. Its legal entity is ETON PHARMACEUTICALS, INC.
Company details
Eton Pharmaceuticals formed by Imprimis Pharmaceuticals and is a developer of sterile injectables. The company is developing and commercialising two of Imprimis patent-pending sterile injectable drug candidates utilising the FDA 505(b)(2) regulatory pathway. They are adrenocorticotropic hormone (ACTH) analogue (39 amino acid peptide synthetic corticotropin) as a potential competitor to H.P. Acthar gel; and injectable pentoxifylline formulation as a potential treatment for Peyronies disease and an alternative or supplementary therapy to Xiaflex.
- Headquarters Barrington, United States
- Employees 31
- Stage Acquired
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Website etonpharma.com
- Social LinkedIn
- Acquired by Bausch & Lomb (Feb 2019)
- Legal Name Eton Pharmaceuticals, Inc.
- Annual Revenue$79.95 M (USD)104.94as on Dec 31, 2025
- Net Profit-$4.6 M (USD)-20.35as on Dec 31, 2025
- EBITDA$4.12 M (USD)as on Dec 31, 2025
- Total Equity Funding$20.06M (USD)
in 2 rounds
- Latest Funding Round$7.5M (USD), Post-IPO
Apr 2020
- Investors
- Employee Count31
- Investments & AcquisitionsIncrelex
& 1 more
- Acquired byBausch & Lomb
(Feb 2019)
Products & Services of Eton Pharmaceuticals
Eton Pharmaceuticals offers a comprehensive portfolio of products and services, including Alkindi Sprinkle, Galzin, Increlex, and PKU GoLike.
Treatment for rare adrenal conditions in pediatric patients.
Medication for managing Wilson's disease symptoms.
Growth-promoting treatment for severe primary IGF-1 deficiency.
Support for phenylketonuria management through dietary aids.
Funding Insights of Eton Pharmaceuticals
Eton Pharmaceuticals has successfully raised a total of $20.06M across 2 strategic funding rounds. The most recent funding activity was a Post-IPO round of $7.5 million completed in April 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $20.06M
- Total Rounds 2
- Last Round Post-IPO — $7.5M
- First Round $20.06M
(Jun 2017)
All 2 funding rounds of Eton Pharmaceuticals with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Apr 2020 | $7.5M | Post-IPO | – | – | – |
| Jun 2017 | $20.06M | Series A | – | – | – |
1 investors in total: 1 institutional.
Investors in Eton Pharmaceuticals
Eton Pharmaceuticals has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Bausch & Lomb.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Ophthalmic pharmaceuticals and instruments are developed for eye care. | 1853 | bausch.com | Bridgewater, United States |
Investor details for Eton Pharmaceuticals
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
IPO & Listings of Eton Pharmaceuticals
Eton Pharmaceuticals is a publicly listed company on the NASDAQ with ticker symbol ETON in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date13 Nov 2018
- Listed onNASDAQ: ETON
- Listed entityEton Pharmaceuticals, Inc.
- Exchange sectorHealth technology
- ISINUS29772L1089
- Share price$53.33 (-3.48% on the day) · 2026-10-13
- Market capitalisation$1.52B
- Price to earnings141.0
- EPS (diluted, trailing year)$0.38
- Volume (last session)550,948
Financials of Eton Pharmaceuticals
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | $80.0M | -$4.6M | $4.1M |
| 2024 | $39.0M | -$3.8M | -$1.0M |
| 2023 | $31.6M | -$936,000 | -$291,000 |
| 2022 | $21.2M | -$9.0M | -$6.5M |
| 2021 | $21.8M | -$2.0M | -$1.1M |
Detailed financial statements for Eton Pharmaceuticals
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Eton Pharmaceuticals
Eton Pharmaceuticals has strategically engaged in corporate development activities, having acquired 2 companies. Notable acquisitions include Increlex and PKU GOLIKE.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
| increlex.com | 0 | Dec 2024 | •••• | |||
Company offers pre measured packets and bars containing amino acids for the dietary management of phenylketonuria | pkugolike.com | 2022 | Mar 2024 | •••• |
Complete acquisition details for Eton Pharmaceuticals
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Eton Pharmaceuticals
7 dated milestones of Eton Pharmaceuticals across 11 years, from founding to its latest funding, stage changes and deals.
- Founded Eton Pharmaceuticals is founded.
- Funding First funding round of $20.1M.
- IPO Lists on the stock exchange (IPO).
- Exit Acquired by Bausch & Lomb.
- Funding Latest funding round, Post-IPO, of $7.5M.
- Acquisition Acquires PKU GOLIKE.
- Acquisition Acquires Increlex.
Web traffic of Eton Pharmaceuticals
The website of Eton Pharmaceuticals (etonpharma.com) receives about 4.3K visits a month and ranks #3,455,668 among all websites worldwide, #4,499 in Biotechnology and Pharmaceuticals.
- Monthly visits4.3K
▼ 20.2% vs previous month
- Unique visitors2.4K
per month
- Global rank#3,455,668
among all websites
- Category rank#4,499
Health · Biotechnology and Pharmaceuticals
- Bounce rate42%
- Pages per visit1.8
- Average visit34 sec
- DevicesDesktop 36% · Mobile 64%
Top companies in Pharmaceuticals & Distribution
3 companies that operate in the same segment as Eton Pharmaceuticals (Pharmaceuticals & Distribution) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Therapeutics for neurology, oncology, rare, and endocrinology diseases are developed. | 2014 | New York, New York, United States | USD 1.3 B | USD 8.26 M | 750 | |
Developer of pharmaceutical products for treating multiple diseases | 1980 | Thousand Oaks, California, United States | USD 33.23 B | 28,000 | ||
Biopharmaceutical research and drug development are conducted globally by AbbVie. | 2012 | Chicago, Illinois, United States | USD 61.16 B | 55,000 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Eton Pharmaceuticals
Complete news archive for Eton Pharmaceuticals
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Eton Pharmaceuticals
Eton Pharmaceuticals was founded in 2013 and raised its 1st funding round 4 years after it was founded.
Eton Pharmaceuticals is headquartered in Barrington, United States. It is registered at Barrington, Illinois, United States.
Eton Pharmaceuticals is a funded company, having raised a total of $20.06M across 2 funding rounds to date. The company's 1st funding round was a Series A of $20.06M, raised on Jun 2017.
Eton Pharmaceuticals has 31 employees.
Annual revenue of Eton Pharmaceuticals is $79.95M as on Dec 31, 2025.
Eton Pharmaceuticals formed by Imprimis Pharmaceuticals and is a developer of sterile injectables. The company is developing and commercialising two of Imprimis patent-pending sterile injectable drug candidates utilising the FDA 505(b)(2) regulatory pathway. They are adrenocorticotropic hormone (ACTH) analogue (39 amino acid peptide synthetic corticotropin) as a potential competitor to H.P. Acthar gel; and injectable pentoxifylline formulation as a potential treatment for Peyronies disease and an alternative or supplementary therapy to Xiaflex.
Eton Pharmaceuticals offers Alkindi Sprinkle, Galzin, Increlex, and PKU GoLike.
Yes, Eton Pharmaceuticals is publicly traded on NASDAQ under the ticker symbol ETON.
Eton Pharmaceuticals has made 2 acquisitions, including Increlex, and PKU GOLIKE.
Eton Pharmaceuticals has 1 investor. Key investors include Bausch & Lomb.
Eton Pharmaceuticals operates through Eton Pharmaceuticals, Inc..
Yes. Eton Pharmaceuticals was acquired by Bausch & Lomb in February 2019.